Inference

Executive Summary

Inference is a San Francisco-based company providing full-spectrum biometrics support for clinical trials, leveraging AI and machine learning to enhance data monitoring committee (DMC) expertise and regulatory-ready analyses. Founded in 2017, the company has established itself as a trusted partner for sponsors, delivering comprehensive services from trial design through BLA and NDA submissions. Its technology-driven approach aims to accelerate decision-making and improve the efficiency and confidence of clinical development processes. Inference operates in the intersection of AI/ML and digital health, targeting the growing demand for advanced analytics in clinical research. As a private company currently in Phase 2 of its development, Inference is poised to scale its offerings amid increasing regulatory complexities and the need for robust biometrics solutions. With no disclosed funding or valuation, the company's progress will likely depend on securing strategic partnerships and contracts with pharmaceutical sponsors. The expected catalysts include the launch of an enhanced AI analytics platform, potential collaborations with top-20 pharma companies, and involvement in high-stakes FDA submissions. These milestones could significantly strengthen Inference's market position and drive adoption of its services.

Upcoming Catalysts (preview)

• Q3 2026Launch of enhanced AI-powered analytics platform70% success
• Q4 2026Key partnership with a top-20 pharmaceutical company60% success
• Q2 2026Support for a high-profile FDA submission (BLA/NDA)80% success